WEKO3
アイテム
Phase I/II trial of definitive carbon ion radiotherapy for prostate cancer: evaluation of shortening of treatment period to 3 weeks.
https://repo.qst.go.jp/records/47514
https://repo.qst.go.jp/records/47514363ca69a-1ce2-45be-b472-f3edbecaf1fb
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2016-08-26 | |||||
タイトル | ||||||
タイトル | Phase I/II trial of definitive carbon ion radiotherapy for prostate cancer: evaluation of shortening of treatment period to 3 weeks. | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
Nomiya, T
× Nomiya, T× Tsuji, H× Maruyama, K× Toyama, S× Suzuki, H× Akakura, K× Shimazaki, J× Nemoto, K× Kamada, T× Tsujii, H× 野宮 琢磨× 辻 比呂志× 丸山 克也× 鎌田 正× 辻井 博彦 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Background:The purpose of this study was to evaluate the feasibility of a new shortened 3-week treatment schedule of carbon ion radiotherapy (CIRT) for prostate cancer.Methods:Beginning in May 2010, patients with T1b-T3bN0M0, histologically proven prostate adenocarcinoma were enrolled in the phase II trial of CIRT. Patients received 51.6 GyE in 12 fractions over 3 weeks (protocol 1002). The primary end point was defined as the incidence of late adverse events that were evaluated based on the Common Terminology Criteria for Adverse Events version 4.0. Biochemical failure was determined using the Phoenix definition (nadir +2.0 ng ml(-1)).Results:Forty-six patients were enrolled, and all patients were included in the analysis. The number of low-, intermediate-, and high-risk patients was 12 (26%), 9 (20%), and 25 (54%), respectively. The median follow-up period of surviving patients was 32.3 months. Two patients had intercurrent death without recurrence, and the remaining 44 patients were alive at the time of this analysis. In the analysis of late toxicities, grade 1 (G1) rectal haemorrhage was observed in 3 (7%) patients. The incidence of G1 haematuria was observed in 6 (13%) patients, and G1 urinary frequency was observed in 17 (37%) patients. No G2 late toxicities were observed. In the analysis of acute toxicities, 2 (4%) patients showed G2 urinary frequency, and no other G2 acute toxicities were observed.Conclusions:The new shortened CIRT schedule over 3 weeks was considered as feasible. The analysis of long-term outcome is warranted.British Journal of Cancer advance online publication, 10 April 2014; doi:10.1038/bjc.2014.191 www.bjcancer.com. | |||||
書誌情報 |
British journal of cancer 巻 110, 号 10, p. 2389-2395, 発行日 2014-04 |
|||||
出版者 | ||||||
出版者 | Nature Publishing Group on behalf of Cancer Research UK | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 0007-0920 | |||||
PubMed番号 | ||||||
識別子タイプ | PMID | |||||
関連識別子 | 24722181 | |||||
DOI | ||||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1038/bjc.2014.191 | |||||
関連サイト | ||||||
識別子タイプ | URI | |||||
関連識別子 | http://www.nature.com/bjc/journal/v110/n10/full/bjc2014191a.html | |||||
関連名称 | http://www.nature.com/bjc/journal/v110/n10/full/bjc2014191a.html |